JP2004510757A - プロピオン酸誘導体 - Google Patents
プロピオン酸誘導体 Download PDFInfo
- Publication number
- JP2004510757A JP2004510757A JP2002532408A JP2002532408A JP2004510757A JP 2004510757 A JP2004510757 A JP 2004510757A JP 2002532408 A JP2002532408 A JP 2002532408A JP 2002532408 A JP2002532408 A JP 2002532408A JP 2004510757 A JP2004510757 A JP 2004510757A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- amino
- formula
- hydrogen atom
- same
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ALINBDIGGKACCQ-UHFFFAOYSA-N CC(C)(C(O)=O)Oc1ccc(CN(CC(Nc2c(C)cc(C3CCCCC3)cc2)=O)Cc2c(C)nc[o]2)cc1 Chemical compound CC(C)(C(O)=O)Oc1ccc(CN(CC(Nc2c(C)cc(C3CCCCC3)cc2)=O)Cc2c(C)nc[o]2)cc1 ALINBDIGGKACCQ-UHFFFAOYSA-N 0.000 description 1
- CDFHPUQLHMRFBK-UHFFFAOYSA-N CC(C)(C(O)=O)Oc1ccc(CN(CCOC)CC(Nc(cc2)c(C(F)(F)F)cc2Oc2c(cccc3)c3ccc2)=O)cc1 Chemical compound CC(C)(C(O)=O)Oc1ccc(CN(CCOC)CC(Nc(cc2)c(C(F)(F)F)cc2Oc2c(cccc3)c3ccc2)=O)cc1 CDFHPUQLHMRFBK-UHFFFAOYSA-N 0.000 description 1
- WMWPHSMKCKENAQ-UHFFFAOYSA-N CC(C)(C(O)=O)Sc1ccc(CCN(CC(Nc(c(C)c2)cc(C)c2OC)=O)Cc2ccc[o]2)cc1 Chemical compound CC(C)(C(O)=O)Sc1ccc(CCN(CC(Nc(c(C)c2)cc(C)c2OC)=O)Cc2ccc[o]2)cc1 WMWPHSMKCKENAQ-UHFFFAOYSA-N 0.000 description 1
- IXXHAQNTUHZIEY-UHFFFAOYSA-N CC(C)(C(O)=O)Sc1ccc(CN(CC(Nc(cc2Cl)c(C)cc2OC(F)(F)F)=O)Cc2ccc[o]2)cc1 Chemical compound CC(C)(C(O)=O)Sc1ccc(CN(CC(Nc(cc2Cl)c(C)cc2OC(F)(F)F)=O)Cc2ccc[o]2)cc1 IXXHAQNTUHZIEY-UHFFFAOYSA-N 0.000 description 1
- IUYYAQMVYWQJHR-UHFFFAOYSA-N CC(C)(C(O)=O)Sc1ccc(CN(CCOC)CC(Nc(c(C)c2)cc(Cl)c2OC(F)(F)F)=O)cc1 Chemical compound CC(C)(C(O)=O)Sc1ccc(CN(CCOC)CC(Nc(c(C)c2)cc(Cl)c2OC(F)(F)F)=O)cc1 IUYYAQMVYWQJHR-UHFFFAOYSA-N 0.000 description 1
- JGMMSFZTDYOQQQ-UHFFFAOYSA-N CC(C)(C)OC(C(C)(C)Cc1ccc(CN(CC(O)=O)c2ccccc2)cc1)=O Chemical compound CC(C)(C)OC(C(C)(C)Cc1ccc(CN(CC(O)=O)c2ccccc2)cc1)=O JGMMSFZTDYOQQQ-UHFFFAOYSA-N 0.000 description 1
- XDUDZEJYXMAQEA-UHFFFAOYSA-N CC(C)(C)OC(C(C)(C)Oc(cc1)ccc1N)=O Chemical compound CC(C)(C)OC(C(C)(C)Oc(cc1)ccc1N)=O XDUDZEJYXMAQEA-UHFFFAOYSA-N 0.000 description 1
- ZQMNUSDNSIPZKN-UHFFFAOYSA-N CC(C)(C)OC(C(C)(C)Oc1ccc(CN(CC(N(C)c2c(C)cc(C)cc2)=O)Cc2ccc[o]2)cc1)=O Chemical compound CC(C)(C)OC(C(C)(C)Oc1ccc(CN(CC(N(C)c2c(C)cc(C)cc2)=O)Cc2ccc[o]2)cc1)=O ZQMNUSDNSIPZKN-UHFFFAOYSA-N 0.000 description 1
- FSRJGLZCOIIQLV-UHFFFAOYSA-N CC(C)(C)OC(C(C)(C)Oc1ccc(CN(CC(Nc2cccc3c2CCCC3)=O)Cc2ccc(C)[o]2)cc1)=O Chemical compound CC(C)(C)OC(C(C)(C)Oc1ccc(CN(CC(Nc2cccc3c2CCCC3)=O)Cc2ccc(C)[o]2)cc1)=O FSRJGLZCOIIQLV-UHFFFAOYSA-N 0.000 description 1
- GLUOAMHNVSFOEK-UHFFFAOYSA-N CC(C)(C)OC(C(C)(C)Oc1ccc(CN(CC(O)=O)Cc2ccc[o]2)cc1)=O Chemical compound CC(C)(C)OC(C(C)(C)Oc1ccc(CN(CC(O)=O)Cc2ccc[o]2)cc1)=O GLUOAMHNVSFOEK-UHFFFAOYSA-N 0.000 description 1
- ALIRSOWNPPWYFJ-BUHFOSPRSA-N CC(C)(C)OC(C(C)(C)Oc1cccc(/C=C/N(C(c2c3cccc2)=O)C3=O)c1)=O Chemical compound CC(C)(C)OC(C(C)(C)Oc1cccc(/C=C/N(C(c2c3cccc2)=O)C3=O)c1)=O ALIRSOWNPPWYFJ-BUHFOSPRSA-N 0.000 description 1
- NIRQQEDGZDDEEH-UHFFFAOYSA-N CC(C)(C)OC(C(C)(C)Sc1cc(C=O)ccc1)=O Chemical compound CC(C)(C)OC(C(C)(C)Sc1cc(C=O)ccc1)=O NIRQQEDGZDDEEH-UHFFFAOYSA-N 0.000 description 1
- BLHSPSBNSLXADR-UHFFFAOYSA-N CC(C)(C)c(cc1)cc(C)c1NC(CBr)=O Chemical compound CC(C)(C)c(cc1)cc(C)c1NC(CBr)=O BLHSPSBNSLXADR-UHFFFAOYSA-N 0.000 description 1
- YXJHZKFWOWNOBM-UHFFFAOYSA-N CC(C)(C)c(cc1C)ccc1NC(CN(CCOC)Cc(cc1)ccc1OC(C)(C)C(O)=O)=O Chemical compound CC(C)(C)c(cc1C)ccc1NC(CN(CCOC)Cc(cc1)ccc1OC(C)(C)C(O)=O)=O YXJHZKFWOWNOBM-UHFFFAOYSA-N 0.000 description 1
- NQRCSCKEMYCSHI-UHFFFAOYSA-N CC(C)c(cc1)cc(C(F)(F)F)c1NC(CBr)=O Chemical compound CC(C)c(cc1)cc(C(F)(F)F)c1NC(CBr)=O NQRCSCKEMYCSHI-UHFFFAOYSA-N 0.000 description 1
- PISBVSQPKHIZOA-UHFFFAOYSA-N CCC(C(Nc1c(C)cc(C)cc1)=O)NCc(cc1)ccc1OC(C)(C)C(OC(C)(C)C)=O Chemical compound CCC(C(Nc1c(C)cc(C)cc1)=O)NCc(cc1)ccc1OC(C)(C)C(OC(C)(C)C)=O PISBVSQPKHIZOA-UHFFFAOYSA-N 0.000 description 1
- XXGZZXKIEQEJDL-UHFFFAOYSA-N CCC(CC)(C(OC(C)(C)C)=O)Sc(cc1)ccc1Br Chemical compound CCC(CC)(C(OC(C)(C)C)=O)Sc(cc1)ccc1Br XXGZZXKIEQEJDL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/18—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10049208 | 2000-10-05 | ||
| DE10124905A DE10124905A1 (de) | 2000-10-05 | 2001-05-22 | Propionsäurederivate |
| PCT/EP2001/011005 WO2002028821A2 (de) | 2000-10-05 | 2001-09-24 | Propionsäurederivate mit ppar-alpha aktivierenden eigenschaften. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2004510757A true JP2004510757A (ja) | 2004-04-08 |
Family
ID=26007267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002532408A Pending JP2004510757A (ja) | 2000-10-05 | 2001-09-24 | プロピオン酸誘導体 |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1328508A2 (pt) |
| JP (1) | JP2004510757A (pt) |
| CN (1) | CN1479716A (pt) |
| AU (1) | AU2001293838A1 (pt) |
| BG (1) | BG107684A (pt) |
| BR (1) | BR0114437A (pt) |
| CA (1) | CA2424540A1 (pt) |
| CZ (1) | CZ2003964A3 (pt) |
| EE (1) | EE200300140A (pt) |
| HN (1) | HN2001000223A (pt) |
| HR (1) | HRP20030346A2 (pt) |
| HU (1) | HUP0302306A3 (pt) |
| IL (1) | IL155125A0 (pt) |
| MA (1) | MA25917A1 (pt) |
| MX (1) | MXPA03002901A (pt) |
| NO (1) | NO20031517L (pt) |
| NZ (1) | NZ525119A (pt) |
| PL (1) | PL361162A1 (pt) |
| RU (1) | RU2003112968A (pt) |
| SK (1) | SK4132003A3 (pt) |
| UY (1) | UY26951A1 (pt) |
| WO (1) | WO2002028821A2 (pt) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006503916A (ja) * | 2002-10-21 | 2006-02-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換テトラリンおよびインダン |
| JP2006503915A (ja) * | 2002-10-21 | 2006-02-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換テトラリンおよびインダンを用いたｘ症候群の治療 |
| JP2006503917A (ja) * | 2002-10-21 | 2006-02-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換テトラリンおよびインダンそしてこれらの使用 |
| JP2010280592A (ja) * | 2009-06-03 | 2010-12-16 | Aska Pharmaceutical Co Ltd | ラクタム化合物又はその塩及びｐｐａｒ活性化剤 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10151390A1 (de) * | 2001-10-18 | 2003-05-08 | Bayer Ag | Essigsäurederivate |
| GB0214254D0 (en) * | 2002-06-20 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| US7504433B2 (en) | 2003-01-06 | 2009-03-17 | Eli Lilly And Company | Thiophene derivative PPAR modulators |
| MXPA06002310A (es) | 2003-08-29 | 2006-05-25 | Ono Pharmaceutical Co | Compuesto capaz de enlazarse al receptor s1p y uso farmaceutico del mismo. |
| AR048931A1 (es) | 2004-04-21 | 2006-06-14 | Janssen Pharmaceutica Nv | Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis |
| CN100344618C (zh) | 2004-05-24 | 2007-10-24 | 北京摩力克科技有限公司 | 作为hPPARα和hPPARγ激动剂的N－芳丙烯酰基取代的酪氨酸衍生物 |
| KR100699928B1 (ko) | 2004-10-05 | 2007-03-26 | 재단법인서울대학교산학협력재단 | 퍼록시솜 증식자 활성화 수용체 알파 리간드를 제조하기위한 중간체의 제조방법 |
| ES2378776T3 (es) | 2004-12-13 | 2012-04-17 | Ono Pharmaceutical Co., Ltd. | Derivado de ácido aminocarboxílico y uso medicinal del mismo |
| CN101054372B (zh) * | 2006-04-11 | 2010-10-13 | 中国科学院上海药物研究所 | 嘧啶取代苯丙酸衍生化合物、其制法和在治疗多囊肾疾病中的用途 |
| WO2010064633A1 (ja) | 2008-12-01 | 2010-06-10 | 田辺三菱製薬株式会社 | チアゾール環を含むカルボン酸誘導体およびその医薬用途 |
| UY34200A (es) | 2011-07-21 | 2013-02-28 | Bayer Ip Gmbh | 3-(fluorovinil)pirazoles y su uso |
| CN107406484A (zh) * | 2014-12-11 | 2017-11-28 | 中化帝斯曼制药有限公司荷兰公司 | 酰化环状肽的方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2320387A1 (de) * | 1973-04-21 | 1974-10-31 | Boehringer Mannheim Gmbh | Phenoxyalkylcarbonsaeurederivate und verfahren zur herstellung derselben |
| GB9822473D0 (en) * | 1998-10-16 | 1998-12-09 | Glaxo Group Ltd | Chemical compounds |
-
2001
- 2001-09-24 WO PCT/EP2001/011005 patent/WO2002028821A2/de active IP Right Grant
- 2001-09-24 IL IL15512501A patent/IL155125A0/xx unknown
- 2001-09-24 PL PL01361162A patent/PL361162A1/xx not_active Application Discontinuation
- 2001-09-24 CZ CZ2003964A patent/CZ2003964A3/cs unknown
- 2001-09-24 HU HU0302306A patent/HUP0302306A3/hu unknown
- 2001-09-24 EE EEP200300140A patent/EE200300140A/xx unknown
- 2001-09-24 RU RU2003112968/04A patent/RU2003112968A/ru not_active Application Discontinuation
- 2001-09-24 EP EP01974287A patent/EP1328508A2/de not_active Withdrawn
- 2001-09-24 SK SK413-2003A patent/SK4132003A3/sk not_active Application Discontinuation
- 2001-09-24 MX MXPA03002901A patent/MXPA03002901A/es unknown
- 2001-09-24 BR BR0114437-5A patent/BR0114437A/pt not_active IP Right Cessation
- 2001-09-24 CA CA002424540A patent/CA2424540A1/en not_active Abandoned
- 2001-09-24 NZ NZ525119A patent/NZ525119A/en unknown
- 2001-09-24 JP JP2002532408A patent/JP2004510757A/ja active Pending
- 2001-09-24 CN CNA018200885A patent/CN1479716A/zh active Pending
- 2001-09-24 AU AU2001293838A patent/AU2001293838A1/en not_active Abandoned
- 2001-10-03 UY UY26951A patent/UY26951A1/es not_active Application Discontinuation
- 2001-10-04 HN HN2001000223A patent/HN2001000223A/es unknown
-
2003
- 2003-03-28 BG BG107684A patent/BG107684A/bg unknown
- 2003-04-03 NO NO20031517A patent/NO20031517L/no not_active Application Discontinuation
- 2003-04-04 MA MA27091A patent/MA25917A1/fr unknown
- 2003-05-02 HR HR20030346A patent/HRP20030346A2/hr not_active Application Discontinuation
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006503916A (ja) * | 2002-10-21 | 2006-02-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換テトラリンおよびインダン |
| JP2006503915A (ja) * | 2002-10-21 | 2006-02-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換テトラリンおよびインダンを用いたｘ症候群の治療 |
| JP2006503917A (ja) * | 2002-10-21 | 2006-02-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換テトラリンおよびインダンそしてこれらの使用 |
| JP2010280592A (ja) * | 2009-06-03 | 2010-12-16 | Aska Pharmaceutical Co Ltd | ラクタム化合物又はその塩及びｐｐａｒ活性化剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0302306A3 (en) | 2005-02-28 |
| CA2424540A1 (en) | 2003-04-02 |
| PL361162A1 (en) | 2004-09-20 |
| MA25917A1 (fr) | 2003-10-01 |
| SK4132003A3 (en) | 2004-02-03 |
| CN1479716A (zh) | 2004-03-03 |
| UY26951A1 (es) | 2002-06-20 |
| BR0114437A (pt) | 2003-07-01 |
| EP1328508A2 (de) | 2003-07-23 |
| MXPA03002901A (es) | 2003-10-15 |
| RU2003112968A (ru) | 2004-09-20 |
| HN2001000223A (es) | 2001-10-25 |
| WO2002028821A3 (de) | 2002-08-15 |
| NZ525119A (en) | 2005-04-29 |
| WO2002028821A2 (de) | 2002-04-11 |
| AU2001293838A1 (en) | 2002-04-15 |
| HUP0302306A2 (hu) | 2003-10-28 |
| BG107684A (bg) | 2003-10-31 |
| EE200300140A (et) | 2003-08-15 |
| CZ2003964A3 (cs) | 2003-08-13 |
| HRP20030346A2 (en) | 2005-04-30 |
| NO20031517L (no) | 2003-05-28 |
| IL155125A0 (en) | 2003-10-31 |
| NO20031517D0 (no) | 2003-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6750236B2 (en) | Propionic acid derivatives | |
| RU2563639C2 (ru) | Замещенные соединения амида | |
| JP2004510757A (ja) | プロピオン酸誘導体 | |
| US7553867B2 (en) | Furan or thiophene derivative and medicinal use thereof | |
| EP1553075B1 (en) | Lpa receptor antagonists | |
| TWI445529B (zh) | 經醯基胺基取代之稠合環戊烷羧酸衍生物及其作為醫藥品之用途 | |
| JP5632612B2 (ja) | ラクタム化合物又はその塩及びｐｐａｒ活性化剤 | |
| WO2005012221A1 (ja) | ジフェニルエーテル化合物、その製造方法および用途 | |
| SK14922003A3 (sk) | Modulátory receptorov aktivovaných proliferátormi peroxizómov (PPAR) | |
| AU2005304962A1 (en) | Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof | |
| JP2002537286A (ja) | チオアミド誘導体 | |
| WO2007085136A1 (fr) | Dérivés de 1,3-benzodioxolecyclopentène, procédé de préparation et applications médicales | |
| TW200521108A (en) | Compounds having lysophosphatidic acid receptor(LPA)-antagonizing effect and their use | |
| MX2007007433A (es) | Nuevos derivados de ciclohexano. | |
| KR20130099110A (ko) | 치환 아미드 화합물 | |
| EP1654247B1 (en) | Alkynyl aryl carboxamides | |
| AU2003241579B9 (en) | Amide linker peroxisome proliferator activated receptor modulators | |
| ES2279310T3 (es) | Derivados de oximas heterociclicas, su procedimiento de preparacion y su utilizacion en el tratamiento de la diabetes tipo ii. | |
| EP1726586A1 (en) | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | |
| KR20030059175A (ko) | Ｐｐａｒ-알파 활성화 성질을 갖는 프로피온산 유도체 | |
| JP2005035966A (ja) | フランまたはチオフェン誘導体およびその医薬用途 | |
| ES2352071T3 (es) | Derivados de tirosina sustituidos con n-fenilacroloilo como agonostas de hppar alfa y de hppar gama. | |
| KR20110077018A (ko) | 갑상선 수용체 리간드 | |
| BRPI0912224B1 (pt) | Derivados de ácido ciclopentanocarboxílico fundido substituído por acilamino, processo para sua preparação, composição farmacêutica contendo os mesmos e seu uso |